New Compounds II

Abstract

The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as such as inflammatory diseases and immune disorders.

1 . A compound of formula (I), 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, geometrical isomer, tautomer, optical isomer or N-oxide thereof, wherein: 
         R 1  is one, two or three substituents independently selected from halogen, cyano, C 1-6 -alkyl, halo-C 1-6 -alkyl and C 1-6 -alkoxy; 
         R 2  is a 4- to 7-membered saturated or partially saturated heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, S and N(R 3 ), and wherein ring carbon atoms are optionally substituted with R 4 ; 
         R 3  is selected from hydrogen, C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, cyano-C 1-6 -alkyl, halo-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1-6 -acyl and C 1-6 -alkylsulfonyl; 
         R 4  is selected from halogen, hydroxy, C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, cyano-C 1-6 -alkyl, halo-C 1-6 -alkyl and C 1-6 -alkoxy; and 
         a is 0, 1 or 2; 
         provided that the compound is not: 
         3-(3,4-dichlorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine, or 
         1-(1-methylpiperidin-4-yl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]-pyridine. 
       
     
     
         2 . A compound according to  claim 1  having formula (I′), 
       
         
           
           
               
               
           
         
         wherein R 1  is selected from halogen, cyano and C 1-4 -alkyl; 
         R 2  is a 5- to 6-membered saturated or partially saturated heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, S and N(R 3 ), and wherein ring carbon atoms are optionally substituted with R 4 ; 
         R 3  is selected from hydrogen, C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, cyano-C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl, C 1-4 -acyl and C 1-4 -alkylsulfonyl; 
         R 4 , if present, is independently selected from C 1-4 -alkyl, halo-C 1-4 -alkyl, hydroxy-C 14 -alkyl and C 1-4 -alkoxy-C 1-4 -alkyl; and 
         a is 0 or 1. 
       
     
     
         3 . A compound according to  claim 1  having formula (I″), 
       
         
           
           
               
               
           
         
         wherein R 1  is selected from halogen, cyano and C 1-4 -alkyl; 
         R 2  is a saturated 5- to 6-membered heterocyclic ring containing 1 heteroatom selected from O and N(R 3 ), and wherein ring carbon atoms are optionally substituted with R 4 ; 
         R 3  is hydrogen, C 1-4 -alkyl or cyano-C 1-4 -alkyl; and 
         R 4 , if present, is independently methyl or ethyl. 
       
     
     
         4 . A compound according to  claim 1 , which is selected from:
 3-(4-Fluorophenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridine;   3-(4-Chlorophenyl)-2-(tetrahydro-2H-pyran-4-yl)-2H-pyrazolo[4,3-c]pyridine;   3-(4-Methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridine;   3-(4-Chlorophenyl)-1-[(3R)-tetrahydrofuran-3-yl]-1H-pyrazolo[4,3-c]pyridine;   3-(4-Chlorophenyl)-1-piperidin-4-yl-1H-pyrazolo[4,3-c]pyridine;   3-(4-Chlorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine;   {4-[3-(4-Chlorophenyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]piperidin-1-yl}-acetonitrile;   3-(4-Chlorophenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazolo[4,3-c]-pyridine;   3-(4-Chlorophenyl)-1-[1-(methylsulfonyl)piperidin-4-yl]-1H-pyrazolo[4,3-c]-pyridine;   1-(1-Acetylpiperidin-4-yl)-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine;   3-(4-Chlorophenyl)-1-[1-(2-methoxyethyl)piperidin-4-yl]-1H-pyrazolo[4,3-c]-pyridine;   3-(4-Chlorophenyl)-1-piperidin-3-yl-1H-pyrazolo[4,3-c]pyridine;   3-(4-Chlorophenyl)-1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazolo[4,3-c]pyridine;   3-(4-Chlorophenyl)-1-(tetrahydrofuran-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine;   3-(4-Chlorophenyl)-1-(1-ethylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine;   3-(4-Chlorophenyl)-1-(1-isopropylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine;   3-(4-Fluorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine;   3-(4-Fluorophenyl)-1-piperidin-4-yl-1H-pyrazolo[4,3-c]pyridine;   4-[1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]benzonitrile; and   4-[1-(1-Methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]benzonitrile.   
     
     
         5 . A pharmaceutical formulation comprising a compound according to  claim 1  as an active ingredient, in combination with a pharmaceutically acceptable diluent or carrier. 
     
     
         6 . The pharmaceutical formulation of  claim 5  wherein the active ingredient is present in an effective amount for the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder. 
     
     
         7 . The pharmaceutical formulation according to  claim 6 , wherein the inflammation or inflammatory disease or immune or autoimmune disorder is arthritis, synovitis, vasculitis, a condition associated with inflammation of the bowel, atherosclerosis, multiple sclerosis, Alzheimer's disease, vascular dementia, a pulmonary inflammatory disease, a fibrotic disease, an inflammatory disease of the skin, systemic inflammatory response syndrome, sepsis, an inflammatory and/or autoimmune condition of the liver, diabetes (type I or II) and/or the complications thereof, chronic heart failure, congestive heart failure, an ischemic disease or myocardial infarction and/or the complications thereof. 
     
     
         8 . The pharmaceutical formulation according to  claim 6 , wherein the inflammatory disease is vasculitis. 
     
     
         9 . The pharmaceutical formulation according to  claim 6 , wherein the inflammation or inflammatory disease or immune or autoimmune disorder is rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, irritable bowel syndrome, asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome, idiopathic pulmonary fibrosis, cardiac fibrosis, systemic sclerosis, contact dermatitis, atopic dermatitis, psoriasis, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, sclerosing cholangitis, autoimmune cholangitis, stroke, or ischemia-reperfusion injury.